Objectives Rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome (pSS) share many clinical manifestations and serological features. The aim of this study was to ...

Objectives Oligoarticular psoriatic arthritis (PsA) is frequent but rarely studied. The objective was to assess the efficacy of apremilast in early oligoarticular PsA. Methods FOREMOST (NCT03747939) ...

Objective To comparatively analyse the aberrant affinity maturation of the antinuclear and rheumatoid factor (RF) B cell repertoires in blood and tissues of patients with Sjögren’s syndrome (SjS) ...

Background Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These patients can be ...

Objective To evaluate the effectiveness and safety of secukinumab in patients with a mucosal and articular Behçet’s phenotype resistant to conventional and biologic treatment. Methods A multicentre ...

26 University of Modena and Reggio Emilia, Rheumatology Unit, Modena, Italy 27 University of Modena and Reggio Emilia, Rheumatology Unit, Modena, Italy 28 University Hospital of Parma, Internal ...

Correspondence to Dr Elizabeth R Volkmann, Department of Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA 90095, USA; evolkmann{at}mednet.ucla.edu ...

Correspondence to Professor Tsutomu Takeuchi, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan; tsutake{at}z5.keio.jp Objectives ...

1 Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA 2 Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, UT, USA ...

Objectives To investigate the ability of high-sensitivity C-reactive protein (hsCRP) and S100A12 to serve as predictive biomarkers of successful drug withdrawal in children with clinical remission of ...

The therapeutic management of Sjögren syndrome (SjS) has not changed substantially in recent decades: treatment decisions remain challenging in clinical practice, without a specific therapeutic target ...

Background Targeting interleukin (IL)-6 has become a major therapeutic strategy in the treatment of immune-mediated inflammatory disease. Interference with the IL-6 pathway can be directed at the ...